📢 Join us for ASPIRE Consortium's Global Session 🌍 Collaborating Across Europe: Advancing Care for irAEs 🎙️ Featuring @drjnaidoo.bsky.social + panel 📅 Sept 15, 2025 🕒 Time: 15:00–16:00 (Central US Time) 💻 Zoom Link: partners.zoom.us/j/82978479128 🔢 Meeting ID: 829 7847 9128 @ascocancer.bsky.social

Mark your calendars! ASPIRE-IOTOX Symposium April 24-25, 2026 at MD Anderson Cancer Center #irAE #immunotherapy @sitcancer.bsky.social @ascocancer.bsky.social @funchainmd.bsky.social @kerryreynoldsmd.bsky.social @kmittalmd.bsky.social @mdanderson.bsky.social

Mark your calendars! ASPIRE-IOTOX Symposium April 24-25, 2026 at MD Anderson Cancer Center #irAE #immunotherapy @sitcancer.bsky.social @ascocancer.bsky.social @funchainmd.bsky.social @kerryreynoldsmd.bsky.social @kmittalmd.bsky.social @mdanderson.bsky.social

Check out the Aug 2025 #ASPIRE newsletter to hear the latest in #irAEs. Do not miss our quarterly case conference Tues, Aug 19th at 5:30pm CST. @ascocancer.bsky.social @kerryreynoldsmd.bsky.social @funchainmd.bsky.social @kmittalmd.bsky.social mailchi.mp/759095cedbb0...

📘 Just launched: the first-ever clinical casebook focused solely on immune-related toxicities. 65 expert-contributed cases across 10+ organ systems. Essential reading for the #irAE frontlines. Grab your copy 👉 link.springer.com/book/10.1007... #irAE #OncologyBooks @ascocancer.bsky.social #ASPIRE

🧠 Stay sharp with the latest in #irAE research! From duplilumab in cutaneous toxicities to survival outcomes with inpatient ICI use—our curated #ASPIRE reading list 🔥. Start reading now in our latest newsletter: mailchi.mp/325da8534919... #Immunotherapy #irAE #MedEd @kmittalmd.bsky.social

Missed #ASPIRE June 17 webinar? 🎥 Now available on-demand! Dive into cutting-edge #ASCO updates on #irAE education, biomarkers, & translation. Must watch the evolving #immunotherapy landscape. 🎯 Link in our latest newsletter: mailchi.mp/325da8534919... @funchainmd.bsky.social

Wrapping up #ASCO24 with this thought: let’s get more people under the survival curve and lift it up - it might be prolonged survival, it might even be cure. Every moment counts. May we all walk into our post ASCO lives inspired ✨ 📈 @ascocancer.bsky.social @aspire-cop.bsky.social

🚀 That's a wrap #ASCO25! Join ASCO’s #ASPIRE Community of Practice, the go-to hub for clinicians addressing immune-related toxicities! 🌟 FREE access for non-oncologists (for a limited time) 💬 Engage in virtual meetings, expert discussions, and access curated content! docs.google.com/forms/d/1zfl...

Alright y’all - last day of #irAE content at #ASCO25 @aspire-cop.bsky.social @ascocancer.bsky.social Monday 6/2 11:30a Bi/Multi-specific Antibodies S406 ➡️Giuseppe Curigliano ➡️Enriquita Felip ➡️Funda Meric Bernstam 3p Beyond Checkpoint E450b ➡️me 😇 ➡️Evan Lipson ➡️Jason Luke

Phase II ipi nivo rela with IL6 inhibitor sarilumab with ORR 68% - highest reported with IO - and grade 3/4 irAEs 12% - lowest reported with combination IO Jan Mehnert @nyulangone.bsky.social #ASCO25 @ascocancer.bsky.social @aspire-cop.bsky.social

Melanoma rapid #3 ➡️ High fiber diet of 30-50g daily is tolerable, pCR 57% in neoadj group, grade 3+ irAE 28.8% Took 400 patients screened to enroll 45 🤔 Yiufan Qiu @mdanderson.bsky.social #ASCO25 @ascocancer.bsky.social @aspire-cop.bsky.social

Melanoma rapid orals #5 ➡️ single dose of neoadj ipi 3 + nivo 1 with 59% major pathological response and 9% grade 3+ TRAE. CD8 PET not predictive. Sarah Lochrin @mskcc.bsky.social #ASCO25 @ascocancer.bsky.social @aspire-cop.bsky.social

Neoadj ipi/nivo is clear winner in melanoma, prompting Genevieve Boland and Diwakar Davar to discuss the CONSTANT communication required between med onc/ surg onc (and relevant subspecialists) perioperatively to address ir-AI or colitis #ASCO25 #irAE @ascocancer.bsky.social @aspire-cop.bsky.social

Honoring all those whose lives have been touched by cancer - your story is unique and powerful, I see you! #NCSD25

Starting soon! More great #irAE content at #ASCO25, including CAR-T and BiTES @kmittalmd.bsky.social @funchainmd.bsky.social @kerryreynoldsmd.bsky.social #ASPIRE

Such important work @aspire-cop.bsky.social team. Crucial to collect the right info to improve our understanding of immunotherapy toxicities and plan the right supportive care for our patients #IOtox #supportivecare #immunotherapy

Thank you to the @aspire-cop.bsky.social executive committee for giving me the opportunity to present at this exciting education session at @ascocancer.bsky.social #asco25

@aspire-cop.bsky.social The very first ASPIRE CoP meeting on #irAE! A historic moment!

Starting in 5 min! Be a part of history at the first meeting of @aspire-cop.bsky.social #irAE #ASCO25 @ascocancer.bsky.social

@mazietsangmd.bsky.social describing how to "connect the dots" of #irAE multidisciplinary management across academic and community cancer centers #ASPIRE @ascocancer.bsky.social @funchainmd.bsky.social @kerryreynoldsmd.bsky.social @kmittalmd.bsky.social

Did you know the ICD10 codes to identify patients experiencing immunotherapy toxicity? @kmittalmd.bsky.social presents these codes as a system-based approach to capture #irAE impact @funchainmd.bsky.social @kerryreynoldsmd.bsky.social @mazietsangmd.bsky.social @ascocancer.bsky.social

@kmittalmd.bsky.social presents #ASPIRE #ASCO25 community united in "Advancing Clinical Care, Research, and Advocacy in Immunotherapy-Related Adverse Events" #irAE @funchainmd.bsky.social @kerryreynoldsmd.bsky.social @ascocancer.bsky.social @mazietsangmd.bsky.social @advocatecollab.bsky.social

Kathryn Bollin, MD's #ASCO25 community oncology perspective on "Getting Practical About Care Transitions" in patients with #irAE #OncSky. "Access to immunotherapy has far outpaced evidence to inform how to manage the related side effects" @ascocancer.bsky.social #ASPIRE @pateloncology.bsky.social

@kerryreynoldsmd.bsky.social presents the "The Who, What, Where of immunotherapy toxicity" #ASCO25 #ASPIRE @kmittalmd.bsky.social @funchainmd.bsky.social @mazietsangmd.bsky.social

So proud of @pallonccop.bsky.social @mazietsangmd.bsky.social! Make sure you stop by her session at #ASCO25 ! @aspire-cop.bsky.social Optimizing the Management of Immune-Related Toxicities Across Care Settings dailynews.ascopubs.org/do/optimizin...

🎉 Big news! Today marks the first gathering of ASCO's latest COP—ASPIRE! 🚀 Join us for the #ASPIRE COP meeting TODAY from 4-6 PM CST in Room E253cd. Let’s connect and collaborate! Don’t miss out! 🤝✨ @ascocancer.bsky.social @funchainmd.bsky.social @kerryreynoldsmd.bsky.social @kmittalmd.bsky.social

Check out the special edition of the #ASPIRE COP newsletter. A curated list of #irAE #ASCO25 sessions & abstracts, the COP, and more! mailchi.mp/39a03f41af5e... @funchainmd.bsky.social @kerryreynoldsmd.bsky.social @kmittalmd.bsky.social @realbowtiedoc.bsky.social @mazietsangmd.bsky.social

Next up on Friday 5/30, make history at the first ever @aspire-cop.bsky.social onsite meeting!!This year we are officially sanctioned by @ascocancer.bsky.social so all balloons and signs can stay up 🥳🎈 bsky.app/profile/aspi...

Mark your calendars! The first F2F #ASCO25 #ASPIRE CoP - Friday, May 30, 4:00 to 6:00 PM CST in Room E253cd. #irAE www.asco.org/annual-meeti... @ascocancer.bsky.social @funchainmd.bsky.social @kerryreynoldsmd.bsky.social @sarahlowry.bsky.social @ericroeland.bsky.social @advocatecollab.bsky.social

🚨 Exciting #irAE insights coming your way at #ASCO25! 🌟 Join us on June 1, 4:30PM - 5:45PM CST for "Toxicities of Immunotherapies Including CAR T-Cell Therapy." Don't miss the expertise of @michaeldjain.bsky.social Stephen Ansell, & Jeremy Abramson! @funchainmd.bsky.social @kmittalmd.bsky.social

🌟Calling all #ASCO25 presenters!🌟 Are you showcasing an #irAE poster? #ASPIRE wants to spotlight your incredible work! 🙌 Join us in advancing knowledge in this vital field!✨ @ascocancer.bsky.social @kmittalmd.bsky.social @funchainmd.bsky.social @kerryreynoldsmd.bsky.social @oncoalert.bsky.social

More #irAE #ASPIRE content at #ASCO25 “Toxicities of Immunotherapies Including CAR T-Cell Therapy” June 1: 4:30 PM - 5:45 PM CST E451 @michaeldjain.bsky.social Stephen Ansell, Jeremy Abramson @ascocancer.bsky.social @funchainmd.bsky.social @kerryreynoldsmd.bsky.social @kmittalmd.bsky.social #CAR-T

🌟 Got questions about #irAEs? 🤔 What about tumor deposits in the lung or liver—do they heighten the risk? Recent retrospective data from hospitalized patients suggests an association 🚨 jitc.bmj.com/content/13/5... #ASPIRE @aspire-cop.bsky.social @kerryreynoldsmd.bsky.social @funchainmd.bsky.social

Fantastic resource for all things #irae at #asco25. Thank you @ericroeland.bsky.social for collating all the sessions in one place 📋 And don’t forget to check out the link for the IRAE tumor board happening tonight 🗓️. This and much more in this newsletter ⬇️

Presenting our May #ASPIRE newsletter mailchi.mp/0ec7836f3ddc... Check out our #ASCO25 COP meeting #irAEs @ascocancer.bsky.social @sitcancer.bsky.social @myesmo.bsky.social @funchainmd.bsky.social @kerryreynoldsmd.bsky.social @kmittalmd.bsky.social @eladsharonmd.bsky.social @oncoalert.bsky.social

#oncsky #oncologynursing @oncoalert.bsky.social

🚨 #irAE aficionados! 2nd #ASPirE Case Discussion series TODAY - apparently y'all like talking about irAE cases! 🗓️ Tues May 20 ⏰ 6:30pm EDT/3:30pm PDT Feat. endocrine & cardiac cases Hosted by Dr. Mimi Wang @ascocancer.bsky.social @funchainmd.bsky.social @kerryreynoldsmd.bsky.social

TODAY 🥳 Who doesn’t like an irAE case fest Bring your endocrine glands, your cardiac tissue, and some 🍿 6:30 EDT/3:30 PDT Zoom link 👇 @aspire-cop.bsky.social

🌟Join us for a #ASCO25 must-see session: “Connecting the Dots: Strategies for Academic and Community Synergy in Immunotherapy Toxicity Care” on May 30 11:00 AM - 12:15 PM CST in E350! 🗓️✨🙌 #ASPIRE @ascocancer.bsky.social @mazietsangmd.bsky.social @kmittalmd.bsky.social @kerryreynoldsmd.bsky.social

🚨 New from @ascocancer.bsky.social ! #ASPIRE is the #ASCO25 community of practice for all #irAE. Oncologists, nurses, pharmacists AND non-oncology subspecialists —join now for FREE (limited time)! 💥 🔗 t.co/Pv8p49MJ2L @amergastroassn.bsky.social @jrheumatol.bsky.social @societyhospmed.bsky.social

Heading to #ASCO25 this year? Be sure to join us for the first ever #ASPIRE Community of Practice on Friday, May 30th: 4-6pm CST in E253cd. We have a great agenda and opportunity to connect with other #irAE aficionados @ascocancer.bsky.social @funchainmd.bsky.social www.asco.org/annual-meeti...

“What does #ASPIRE mean to you ?” Hear from our members about why YOU should join the ASCO ASPIRE COP #irAE #ASCO25 @ascocancer.bsky.social @kerryreynoldsmd.bsky.social @funchainmd.bsky.social @ericroeland.bsky.social @kmittalmd.bsky.social @oncodaily.bsky.social @sitcancer.bsky.social

🎉 Excited to launch the @ascocancer.bsky.social #ASPIRE Community of Practice! Mark your #ASCO25 calendars: May 30, 4-6pm CST E253cd. Unite to improve the lives of people with #cancer and #irAE @funchainmd.bsky.social @kerryreynoldsmd.bsky.social @oncodaily.bsky.social www.asco.org/annual-meeti...

First post— woo hoo! Join #ASPIRE, the global community advancing clinical care, education, and research in immune-related adverse events (#irAEs). Be part of our 300+ member network dedicated to making a difference! #ASCO25 @funchainmd.bsky.social @ascocaner.bsky.social @oncodaily.bsky.social

🎉 Excited to launch the @ascocancer.bsky.social #ASPIRE Community of Practice! Mark your #ASCO25 calendars: May 30, 4-6pm CST E253cd. Unite to improve the lives of people with #cancer and #irAE @funchainmd.bsky.social @kerryreynoldsmd.bsky.social @oncodaily.bsky.social www.asco.org/annual-meeti...

Interested in #irAEs? Join the Alliance for Support and Prevention of Immune-Related Adverse Events #ASPIRE Follow QR code or Google Form docs.google.com/forms/d/1zfl... @funchainmd.bsky.social @kerryreynoldsmd.bsky.social @kmittalmd.bsky.social @ascocancer.bsky.social @oncodaily.bsky.social